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Abstract
Purpose—The USA has a well-established network of central cancer registries (CCRs) that 
collect data using standardized definitions and protocols to provide population-based estimates of 
cancer incidence. The addition of cervical cancer precursors in select CCR operations would 
facilitate future studies measuring the population-level impact of human papillomavirus (HPV) 
vaccine. To assess the feasibility of collecting data on cervical cancer precursors, we conducted a 
multi-site surveillance study in three state-wide CCRs, to obtain annual case counts and compare 
rates of precursor lesions to those for invasive cervical cancer.
Methods—We developed standardized methods for case identification, data collection and 
transmission, training and quality assurance, while allowing for registry-specific strategies to 
accomplish surveillance objectives. We then conducted population-based surveillance for 
precancerous cervical lesions in three states using the protocols.
Results—We identified 5,718 cases of cervical cancer precursors during 2009. Age-adjusted 
incidence of cervical cancer precursors was 77 (Kentucky), 60 (Michigan), and 54 (Louisiana) per 
100,000 women. Highest rates were observed in those aged 20–29 years: 274 (Kentucky), 202 
(Michigan), and 196 (Louisiana) per 100,000. The variable with the most missing data was race/
ethnicity, which was missing for 13 % of cases in Kentucky, 18 % in Michigan, and 1 % in 
Louisiana. Overall rates of cervical cancer precursors were over sixfold higher than invasive 
cervical cancer rates [rate ratios: 8.6 (Kentucky), 8.3 (Michigan), and 6.2 (Louisiana)].
Conclusions—Incorporating surveillance of cervical cancer precursors using existing CCR 
infrastructure is feasible and results in collection of population-based incidence data. Standardized 
collection of these data in high-quality registry systems will be useful in future activities 
monitoring the impact of HPV vaccination across states. As a result of this study, ongoing 
surveillance of these lesions has now been conducted in four CCRs since 2010.
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Introduction
Since 2006, two human papillomavirus (HPV) vaccines have been commercially available 
for protection against HPV types 16 and 18, which cause approximately 70 % of cervical 
cancers worldwide [1, 2]. Several factors complicate efforts to monitor the population 
impact of HPV vaccine, including multiple clinical outcomes and differing, often extended, 
times to outcome development [3–7]. Cervical cancer, the most important anogenital 
outcome of HPV infection, may take several decades to develop [8], but cervical cancer 
precursors often occur 1–3 years after cervical HPV infection [9–12].
Rates of invasive cervical cancer are estimated through population-based central cancer 
registries (CCRs). Federally funded CCRs exist in all 50 states and are administered through 
the Centers for Disease Control and Prevention’s (CDC) National Program of Cancer 
Registries (NPCR) [13] or the National Cancer Institute’s (NCI) Surveillance, Epidemiology 
and End Results (SEER) Program [14]. Prior to 1996, cases of in situ cervical carcinoma 
were routinely reported to CCRs, but collection was discontinued due to concerns about 
comparability of cases over time because of changes in diagnostic terminology, 
inconsistencies in case definitions used across registries, and increased diagnosis and 
treatment of cervical lesions in outpatient settings [15]. Only one state, Michigan, continued 
to collect data on in situ cervical carcinoma as part of its routine cancer surveillance [16].
The primary objectives of this project were to evaluate the feasibility of population-based 
surveillance of cervical cancer precursors using the existing CCR infrastructure and to 
estimate the 2009 annual incidence of these lesions in participating states. Secondary 
objectives were to develop standardized methods for data collection which would be easily 
transferrable to a larger group of CCRs.
Methods
This project was conducted by CDC, the Kentucky Cancer Registry (KCR), Louisiana 
Tumor Registry (LTR), and Michigan Cancer Surveillance Program (MCSP). The KCR and 
LTR are state-wide registries that participate in both the NPCR and the SEER Program. The 
MCSP participates in NPCR, conducting cancer surveillance for all areas of Michigan 
except metropolitan Detroit, for which cancer surveillance is conducted by a SEER registry; 
for this project, the MCSP collaborated with the Detroit registry to collect state-wide 
Michigan data.
Case definition
Case eligibility was based on pathology report information; cases identified only by 
cytology report were excluded. The case inclusion criteria are provided in Table 1. If more 
than one precancerous cervical lesion was identified for a given patient during a 12 month 
time period, only the earliest occurring lesion was reported. Lesions were classified 
histologically as either squamous or adenocarcinoma in situ (AIS).
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Case-finding
CCRs have exhaustive case-finding protocols for identification of incident cancer cases that 
were utilized to ascertain precancerous cervical lesions; sources included free standing, 
reference, and hospital pathology laboratories. Case-finding was performed by manual 
review of pathology reports or an automated search of electronic records using key words or 
phrases, International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [17] 
codes, International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-
CM) [18] codes or Systematized Nomenclature of Medicine (SNOMED) codes [19, 20]. The 
appropriate ICD-9-CM code was 233.1 [cervical intraepithelial neoplasia grade 3 (CIN3)/
carcinoma in situ (CIS)/severe dysplasia]. For pathology laboratories using the older 
SNOMED Reference Terminology [20], the Legacy Code (M-81402, M-80702, or 
M-80772) was used; those using the newer SNOMED Clinical Terms used both the Concept 
ID (51642000, 59529006, or 20365006) and the Legacy Code. Artificial Intelligence in 
Medicine (AIM) E-Path software [21] was modified to include appropriate search terms and 
screen pathology report text. Hospital registrars and pathology laboratory personnel 
collaborated with CCR staff to implement new E-Path installations and continued previous 
data collection and transmission protocols for a specified time period to ensure data 
collection was complete, transmission was continual, and any installation errors resulting in 
missed cases were quickly identified and corrected.
Cases were submitted to CCRs by pathology laboratories and hospital tumor registries 
according to established protocols within each state. These included:
• Electronic reporting by hospital tumor registries with supporting documentation 
for the primary anatomic site and histology codes.
• Electronic reporting by pathology laboratories (e.g., complete pathology report 
or electronic list with final diagnosis in text).
• Case finding at pathology laboratories by CCR staff.
• Pathology report submission by hospital medical record department or registry 
staff.
Cases added to the registry database were checked for duplicate records; all duplicates were 
removed.
Case follow-back to the original reporting source
Case follow-back [22] (contacting a physician, abstractor, or reporting facility to obtain 
missing information or resolve inconsistencies) was conducted, as necessary, for the 
following data items: lesion behavior; histology; diagnosis date; city, state, and county of 
residence on diagnosis date; birth date; race.
Data abstraction
Once case-finding activities were completed, data elements were abstracted. To maintain 
consistency with registry operations, these elements, a subset of the standard North 
American Association of Central Cancer Registries (NAACCR) variables, were coded using 
NAACCR standards [23]. Only the data elements necessary to identify and characterize 
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cases of cervical cancer precursors were collected, in order to minimize burden on tumor 
registry and CCR staff. These data elements, with the rationale for including each, are listed 
in Table 2.
Quality control and feasibility assessments
CCRs were responsible for ensuring all eligible cervical cancer precursors were identified, 
using existing NPCR and SEER quality control protocols. Case-finding audits (systematic 
review of a sample of cases reported by all sources during a specified time period, coupled 
with verification of cases using a different case-finding methodology) were conducted by 
staff of each registry. Results of these case-finding audits were included in each registry’s 
annual project report.
Additional quality control was conducted by performing checks for duplicate cases, and 
variable-specific checks were used to ensure data values were not missing or invalid. These 
variable-specific checks are briefly described in Table 2. CCRs were encouraged to modify 
standard registry programs such as GenEdits Plus [24] for this purpose. Feasibility of 
implementing this activity at CCRs was assessed by examining numbers and qualifications 
of personnel needed, start-up and on-going costs, and other factors associated with project 
management, data collection, and quality control activities, including implementing changes 
to existing text-screening software, reviewing pathology reports, and conducting follow-up 
activities.
Population denominators
State-specific female populations for each age and race/ethnicity category were derived 
using vintage 2009 bridged race, Hispanic origin, and gender-specific postcensal estimates 
of the resident population of the USA for July 1, 2009, by year, county, and single year of 
age (0, 1, 2, …, 85 years and over) obtained from the National Center for Health Statistics, 
prepared in collaboration with the US Census Bureau [25].
Analysis variables
Cases were classified by histology (squamous or glandular lesions), age (5-year categories, 
except 0–14 and 65+ years), and race/ethnicity [Hispanic (of all races), non-Hispanic white, 
non-Hispanic black, other (Asian, Pacific Islander, American Indian, or Alaska Native), 
unknown]. Hispanic ethnicity was assigned using the NAACCR Hispanic Identification 
Algorithm version 2 [26]. To estimate incidence rates, we allocated cases with missing race 
across the four race/ethnicity categories based on the state-specific proportions of cases with 
known race/ethnicity in each category. Age-adjusted rates were calculated using standard 
SEER procedures and used year 2000 US standard population in 5-year age groups [27]. 
Invasive cervical cancer case counts and rates for year 2009 were derived from NPCR data 
by CDC staff. Invasive squamous lesions were those with ICD-O-3 histology codes 8050–
8084 and 8120–8131; invasive adenocarcinomas had histology codes 8015, 8140–8149, 
8160–8162, 8190–8221, 8260–8337, 8350–8551, 8560, 8570–8576, and 8940–8941.
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Results
Case counts and incidence estimates
We identified a total of 5,718 cases: 1,639 (29 %) from Kentucky, 2,834 (49 %) from 
Michigan, and 1,245 (22 %) from Louisiana (Table 3). Ninety-seven percent of the lesions 
were of squamous cell origin. Overall, the reported histology of cases was 75 % CIN3, 10 % 
CIS, 12 % severe dysplasia, and 3 % AIS.
The highest incidence was observed among women aged 20–29 with slight variation by 
state: 274 per 100,000 in Kentucky, 202 in Michigan, and 196 in Louisiana. Age-adjusted 
incidence of cervical cancer precursors was highest in Kentucky at 77 per 100,000, followed 
by 60 per 100,000 in Michigan and 54 per 100,000 in Louisiana. For each state, age-adjusted 
incidence for cervical cancer precursors was 6–8 times higher than the corresponding 2009 
invasive cervical cancer rate [28] (Table 4). Rate ratios of precancerous to invasive lesions 
were 8.6 for Kentucky, 8.3 for Michigan, and 6.2 for Louisiana. Rate ratios for squamous 
histologies were similar in Kentucky and Michigan (12.5 and 12.4, respectively), but were 
lower for Louisiana (7.4); rates of precancerous and invasive lesions were similar for AIS 
histologies.
The extent of missing values for race/ethnicity varied by state, ranging from 1 % in 
Louisiana to 13 % in Kentucky and 18 % in Michigan. Age-adjusted incidence in Kentucky 
was highest among Hispanics (109 per 100,000) (Table 3). Age-adjusted incidence in 
Louisiana was higher among non-Hispanic whites and blacks (58 and 52 per 100,000, 
respectively) than Hispanics (41). In Michigan, age-adjusted incidence was similar for 
Hispanics (63 per 100,000), non-Hispanic whites (61) and non-Hispanic blacks (68). In all 
three states, age-adjusted incidence was lowest among those of other non-Hispanic race.
Quality control and feasibility assessments
Audits included examination of pathology reports to determine whether the neoplasia 
classification system used resulted in missed cases of pre-invasive cervical lesions. With few 
exceptions, when cytology terminology [29, 30] was used, it was in combination with 
histology terminology, allowing for determination of case eligibility according to the 
established protocol. In Kentucky, 135 (8 %) originally missed cases were subsequently 
identified based on audit activities; in Louisiana, 92 (7 %) missed cases were identified via 
audit. In both states, the majority of the missed cases were identified through pathology 
reports that had not been transmitted electronically. In Michigan, no missed cases were 
identified based on an audit of reports from 10 randomly selected facilities; however, 5 of 
the 274 cases (2 %) from these facilities were misreported as having a cervical cancer 
precursor lesion when they actually had invasive cervical cancer.
In Kentucky, 100 % of cases were reported by pathology laboratories (hospital-based or free 
standing). In Louisiana, 64 % of cases were reported by hospital registrars, 33 % by 
pathology laboratories, and 3 % by physicians. In Michigan, 44 % of cases were reported by 
hospital registrars, 7 % by laboratories, and 48 % by physicians. Electronic reporting was 
used for the majority of cases in Kentucky (79 %) and Louisiana (67 %); fewer cases in 
Michigan were reported electronically (24 %). Electronic reporting reduced reporting burden 
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on facility staff; however, adoption of electronic reporting by facilities during the study 
necessitated facility-specific interactions to identify and resolve implementation problems. 
Audits of electronic reporting helped identify and address software programming errors 
during a 6-month project pilot period (July–December 2008). During this period, 135 (8 %) 
cases in Kentucky were identified as missed by audit; most (81 %) because of logic errors in 
the case-finding software. In Louisiana, most (82 %) eligible cases from a large electronic 
reporting facility were not initially identified by the case-finding software because terms 
were omitted from the software case selection criteria; this was corrected in early 2009. 
Although electronic reports were delivered in a timely fashion, these data were frequently 
incomplete, necessitating case follow-back to the original reporting source and increasing 
operational burden.
In Michigan, where a majority of cases were identified using manual pathology report 
review by hospital tumor registry or CCR staff, specialized training was implemented to 
familiarize abstractors with the case definition and reporting procedures. A presentation was 
given at the Michigan Cancer Registrar’s Association Annual Educational Conference in 
October 2008, and two web-based presentations were conducted in early 2009. A series of 
communications describing the project and implementation protocol also were developed 
and distributed via the MCSP and Detroit registry staff newsletters and e-mails to all 
licensed Michigan pathology facilities.
To re-establish population-based surveillance for cervical cancer precursors in Kentucky and 
Louisiana, an initial development period of 6–12 months was necessary to obtain needed 
approvals (e.g., Institutional Review Board approvals and contracts), conduct staff training 
and facility outreach activities, update existing reporting and data management systems, and 
establish data collection and processing procedures. Facilities which diagnose cervical 
cancer precursors but which do not routinely diagnose other reportable lesions, such as non-
hospital laboratories, also needed to be identified and outreach activities conducted to 
facilitate initiation of routine reporting. Each registry needed 1–1.5 full-time personnel to 
conduct ongoing project management, data collection, and quality control activities, 
including implementing changes to existing text-screening software, reviewing pathology 
reports and conducting follow-up activities. Estimated start-up costs ranged from $80,000 to 
$100,000 for each registry.
Discussion
This is the first report of population-based cervical cancer precursor incidence from multiple 
states since surveillance of in situ cervical carcinoma was discontinued in NPCR/SEER in 
1996 [15]. Since then, changes in diagnostic terminology and increased diagnosis, treatment 
of cervical lesions in outpatient settings, HPV vaccination and the implementation of 
electronic pathology reporting warrant an evaluation of the feasibility of re-instituting 
surveillance for cervical cancer precursors in CCRs. Only one state, Michigan, continued to 
collect in situ cervical carcinoma cases as part of its routine cancer surveillance [16]. We 
observed an age-adjusted cervical cancer precursor incidence of 55 per 100,000 for 
Michigan, which was similar to the incidence of 59.2 reported by Michigan for CIS and 
CIN3 in 2003 [16].
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Cervical cancer precursors are primarily detected through exfoliated cytology (Papanicolaou 
or Pap test), but are diagnosed by histologic evaluation of tissue samples. US nomenclature 
for cervical cytology and histology has changed over time and continues to evolve. The 
Bethesda system [29, 30], currently used for cervical cytology, categorizes most squamous 
lesions as either low- or high-grade squamous intraepithelial lesions (LSIL and HSIL, 
respectively) and glandular lesions as AIS. Histology terminology for squamous lesions 
originally used dysplasia gradations (mild, moderate, severe) with a separate category for 
CIS, and subsequently shifted to CIN grades 1, 2, 3; CIN3 includes CIS [31]. Glandular 
lesions are typically diagnosed histologically as AIS. CIN3 lesions and CIS are consistently 
recognized by pathologists as true cancer precursors because they rarely regress and have 
high potential of progression to invasion [32]; ≥31 % of women with CIN3 lesions who 
received minimal or no treatment developed invasive cervical cancer within 30 years of their 
CIN3 diagnosis [33]. In contrast, CIN2 diagnoses have poor reproducibility [34, 35] and are 
significantly more likely to regress than CIN3 [36]. Although it was thought that CIN grades 
represented a progressive continuum of morphologic changes, the concept that most CIN1 
lesions are self-limited and represent transient HPV infection, while CIN3 lesions represent 
disease with invasive potential, has gained increasing credence [12, 37]. According to this 
view, CIN2 is an equivocal diagnosis reflecting uncertainty regarding whether the lesion 
should appropriately be classified as CIN1 or CIN3.
This has led to the recently proposed Lower Anogenital Squamous Terminology (LAST) 
[31, 38] for HPV-associated lesions, subsequent to implementation of this study. LAST is a 
two-tiered pathology terminology for anogenital squamous lesions, specifically LSIL and 
HSIL; HSIL may be further classified using appropriate CIN terminology, depending on the 
use of biologic markers such as p16 [31]. p16 immunohistochemistry is currently 
recommended to differentiate low-grade lesions from those cervical cancer precursors which 
are the focus of this project. Surveillance of in situ cervical carcinoma was previously 
discontinued in most CCRs in part because of changes in diagnostic terminology and 
concerns regarding use of the two-tiered Bethesda reporting system for histopathology 
diagnoses [15]; implementation of LAST terminology will need to be closely monitored 
over time to determine potential impact on case counts of cervical cancer precursors. 
Maintaining the ability to efficiently preclude non-precursor lesions under LAST 
implementation will depend on availability of sufficient additional information in the 
pathology report (e.g., dysplasia or CIN terminology) or consistent use and reporting of 
appropriate biologic markers.
For this study, the Bethesda terminology, when used, was almost always in combination with 
histology terminology. However, this project was limited only to cases with lesions 
conclusively diagnosed as CIN3, CIS, AIS, or severe dysplasia. Although diagnoses such as 
“CIN2 and CIN3” were eligible for inclusion, other combinations of these terms such as 
“CIN2/3” and “CIN2–3” were considered ambiguous, most likely indicating a lesion that 
was not clearly CIN2 or CIN3. We were not able to rule-out the possibility that combined 
diagnoses other than “CIN2 and CIN3” might have indicated lesions with invasive potential, 
resulting in potentially missed cases.
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We found a slightly higher ratio of cervical precursor incidence relative to invasive cervical 
cancer for Kentucky, compared to Louisiana and Michigan. Proportionally, more electronic 
reporting in Kentucky might have contributed, in part, to this observation; cases were 
reported sooner via electronic reporting, but we did not assess the impact of such reporting 
on case finding. Other factors that might contribute to differences in ratios of pre-invasive to 
invasive cervical lesions across states include differences in population-specific 
demographic factors, regional or state-specific diagnostic coding by pathologists, and 
demographic or geographic variations in cervical cancer screening. In general, higher 
screening rates, followed by appropriate diagnostic procedures, can result in more precursor 
lesion detection and lower incidence of invasive cancer. Assessing or reviewing cervical 
cancer screening practices will be important [39] when trends in cervical cancer precursors 
are used to evaluate the impact of HPV vaccine. Recent guidelines encourage less cervical 
cancer screening among women under age 21 [40–42], so a decrease in rates of cervical 
cancer precursors may reflect reductions in screening and detection, rather than actual 
decreases due to HPV vaccination. Although population-based registries of cervical cancer 
screening do not exist in the USA, self-reported data collected by the Behavioral Risk Factor 
Surveillance System (BRFSS) [43] can be used to monitor population trends in screening. 
BRFSS data show slight declines in percentages of adult women receiving a Pap test from 
2004 to 2010 for Kentucky (85.0 % in 2004 to80.9 % in 2010) and Michigan (86.5–82.4 %). 
Screening in Louisiana varied during this period: 85.2 % (2004), 76.7 % (2008), and 83.1 % 
(2010) [44].
Surveillance methodologies developed for this project are readily transferable to other 
CCRs. Adequate financial resources are needed to conduct surveillance of cervical cancer 
precursors; however, once this data collection activity becomes routine, annual costs may 
decrease somewhat due to fewer resources spent on training and outreach to facilities. 
Estimated start-up expenses may increase a registry’s costs by approximately 10 %, based 
on median annual registry operational costs of $900,000 [45]. Additional study is needed to 
estimate the excess cost of implementing surveillance for precancerous cervical lesions in 
CCRs over time. In 2010, the Los Angeles Cancer Surveillance Program, the CCR for Los 
Angeles County, California, began surveillance of cervical cancer precursors using the 
project protocol. Implementation of this protocol in other CCRs in the United States with 
relatively high burdens of invasive cervical cancers, particularly those with racially and/or 
ethnically diverse populations, would result in the development of a valuable sentinel 
surveillance system for monitoring the impact of HPV vaccine on rates of cervical cancer 
precursors.
A potential limitation for future activities aimed at increasing the number of CCRs 
conducting surveillance for cervical cancer precursors may be the legislative environment in 
a given catchment area. State laws and legislative rules should be reviewed prior to 
surveillance initiation, and appropriate actions can be taken to modify the legislative 
language if it exempts collection of cervical cancer precursors from routine cancer reporting 
requirements. In Kentucky, facilities were mandated to report any lesions specified by the 
KCR, so reporting regulations did not need to be changed; other jurisdictions may have 
similarly worded reporting requirements, which would be much easier to amend than laws. 
To re-establish surveillance of cervical cancer precursors in Louisiana, the LTR worked with 
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the state legislature to change the reporting regulations to include collection of pre-
cancerous lesions specified by the LTR; these changes became effective in 2010.
Another limitation of this project was incomplete race/ethnicity data. These data are likely to 
be incomplete in electronically transmitted pathology reports, which typically do not include 
demographic information that might be available in medical records. Cases with missing 
race/ethnicity data were reallocated to non-missing categories based on state-specific 
proportions of cases with known race/ethnicity. Non-Hispanics of other race, which were 
less than 5 % of the population in each state, may have been somewhat under-represented by 
this reallocation. In addition, Hispanic population data, which may differ across states, may 
underestimate the true population because undocumented workers may be undercounted, 
artificially inflating incidence estimates for Hispanics. Use of multiple imputation [46] may 
be an appropriate alternate method to estimate state-specific race/ethnicity distributions for 
future reporting. Imputation of race/ethnicity data is not typically needed for invasive cancer 
cases because most CCRs have less than 5 % of missing race values for these cases (a 
requirement for receiving NAACCR certification). For our study of cervical cancer 
precursors, only Louisiana used the same procedures to identify race as were used for 
invasive cancers. These included use of a commercially available online record locator 
service and contacting facilities to obtain patient race information. This may explain why 
Louisiana has a very low percentage of cases with missing race.
Population-based surveillance of CIN2, CIN3, and AIS is also being conducted in five 
geographic city- or county-specific areas throughout the USA by CDC’s HPV-IMPACT 
project [47]. Although the total female population included in HPV-IMPACT is much 
smaller (approximately 15 % of the adult female population covered by this project), 
information on screening history and HPV vaccination is also being collected. Another 
project, the New Mexico HPV Pap Registry [48], collects state-wide data on Pap test 
cytology, cervical pathology, and HPV test results on individuals living in New Mexico, 
which, in conjunction with cervical screening histories, will be used to monitor the 
effectiveness of HPV vaccine in this population. In-depth investigations similar to these can 
be readily conducted using the CCR infrastructure developed for this project; special studies 
addressing topical issues in cancer prevention and control are well-supported by SEER and 
NPCR [49, 50]. A feasibility study has been conducted that linked the Michigan cervical 
cancer precursor cases to the state’s immunization information system; this methodology 
will be useful in examining the effect of HPV vaccine on trends in these lesions [51]. 
Population-based studies examining factors associated with distributions of HPV genotypes 
between cases of precancerous cervical lesions also can be conducted using this project’s 
infrastructure [52, 53].
In summary, this project established the feasibility of routine surveillance of cervical cancer 
precursors using the existing CCR infrastructure for collecting high-quality population-
based data. Standardized collection of these data can be used in future projects and analyses 
to monitor the impact of HPV vaccination across states.
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Table 1
Case inclusion criteria, surveillance of cervical cancer precursors, three central cancer registries, United States 
2009
Site (ICD-O-3) C53.0 (endocervix), C53.1 (exocervix), C53.8 (overlapping lesions of cervix uteri) and C53.9 (cervix uteri)
Behavior 2 (in situ or noninvasive)
Histology 8010/2 carcinoma in situ, NOS
8050/2 papillary carcinoma in situ
8052/2 papillary squamous cell carcinoma, noninvasive
8070/2 squamous cell carcinoma in situ, NOS
8071/2 squamous cell carcinoma, keratinizing, NOS, in situ
8072/2 squamous cell carcinoma, large cell, non-keratinizing, in situ
8076/2 squamous cell carcinoma in situ with questionable stromal invasion
8077/2 squamous intraepithelial neoplasia grade III
8140/2 adenocarcinoma in situ
Pathologic classification CIN III, CIS, AIS, severe dysplasia
Case enrollment period January 1, 2009–December 31, 2009
Incident case time period If more than 1 lesion is identified for a patient in a 12-month time period, the earliest lesion is reported
Catchment area Residents of Louisiana, Kentucky or Michigan at time of diagnosis (includes cases diagnosed out-of-state)
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